We develop innovative next-generation therapeutics through RNA research that identifies the root causes of cancer and inflammatory and fibrotic diseases.

NEORNAT Inc. is a first-in-class drug development company that fundamentally redefines the pathophysiology of cancer and inflammatory and fibrotic diseases based on its proprietary RNA platform.

Leveraging our RNA-based core technology that precisely controls immune imbalance in the disease microenvironment, we aim to overcome the limitations of existing therapies and present a new therapeutic paradigm. In particular, we are securing global competitiveness through the development of innovative therapeutics utilizing macrophage reprogramming mechanisms.

Our key pipeline, NRT-YHD, is being advanced as a next-generation RNA immuno-oncology therapy in global clinical development. Along with NRT-FX, which is expanded into metabolic and fibrotic disease treatments, we are implementing a multi-indication therapeutic strategy based on a single platform.

NEORNAT is committed to contributing to the improvement of human health and quality of life through scientific innovation and precision medicine, and we will continue to grow into a global RNA therapeutics company advancing toward commercialization.

Thank you.

NEORNAT Inc. CEO
prof. Suk Woo Nam. PhD